FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Biotech Enterprise Capital Monitor – USA 12/2022”.
The Monitor is a month-to-month printed overview of enterprise capital tendencies within the US-Biotech sector.
As of the tip of December 2022, we establish the next present VC tendencies within the US-Biotech sector:
- In 2022, total Biotech funding within the USA has reached USD 31,894m (-1,027m in comparison with 2021)
- The highest 5 offers exceed USD 340m every, largest transaction amounted to USD 3,000m in Altos Labs
- ARCH Enterprise Companions (USA) is main the High 5 Buyers (by deal quantity), adopted by OrbiMed (USA) and RA Capital Administration (USA)
- Oncology dominates as the highest indication
To entry the total report, please click on right here.
By Dr. Mathias Schott, Johannes Hyperlink and Marcel-Louis Christou.